Pazopanib in renal cell carcinoma.

@article{Ward2010PazopanibIR,
  title={Pazopanib in renal cell carcinoma.},
  author={James E. Ward and Walter M. Stadler},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 24},
  pages={5923-7}
}
Pazopanib is an oral, multitargeted tyrosine kinase inhibitor that has been approved by the U.S. Food and Drug Administration for treatment of patients with advanced renal cell cancer on the basis of a randomized, double-blind, placebo-controlled, phase III trial, which showed that once a day dosing of 800 mg of pazopanib resulted in progression free survival of 9.2 months versus 4.2 months (P < 0.0001). Pazopanib thus joins sorafenib and sunitinib as one of the clinically available VEGF… CONTINUE READING

From This Paper

Topics from this paper.
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…